Interleukin-6/NN
promotes/VBZ
multiple/JJ
myeloma/NN
cell/NN
growth/NN
via/IN
phosphorylation/NN
of/IN
retinoblastoma/NN
protein/NN
./.

Interleukin-6/NN
(/(
IL-6/NN
)/)
mediates/VBZ
autocrine/NN
and/CC
paracrine/NN
growth/NN
of/IN
multiple/JJ
myeloma/NN
(/(
MM/NN
)/)
cells/NNS
and/CC
inhibits/VBZ
tumor/NN
cell/NN
apoptosis/NN
./.
=====
Abnormalities/NNS
of/IN
retinoblastoma/NN
protein/NN
(/(
pRB/NN
)/)
and/CC
mutations/NNS
of/IN
RB/NN
gene/NN
have/VBP
been/VBN
reported/VBN
in/IN
up/IN
to/TO
70/CD
%/NN
of/IN
MM/NN
patients/NNS
and/CC
80/CD
%/NN
of/IN
MM-derived/JJ
cell/NN
lines/NNS
./.
=====
Because/IN
dephosphorylated/VBN
(/(
activated/VBN
)/)
pRB/NN
blocks/VBZ
transition/NN
from/IN
G1/NN
to/TO
S/NN
phase/NN
of/IN
the/DT
cell/NN
cycle/NN
whereas/IN
phosphorylated/VBN
(/(
inactivated/VBN
)/)
pRB/NN
releases/VBZ
this/DT
growth/NN
arrest/NN
,/,
we/PRP
characterized/VBD
the/DT
role/NN
of/IN
pRB/NN
in/IN
IL-6-mediated/JJ
MM/NN
cell/NN
growth/NN
./.
=====
Both/CC
phosphorylated/VBN
and/CC
dephosphorylated/VBN
pRB/NN
were/VBD
expressed/VBN
in/IN
all/DT
serum-starved/JJ
MM/NN
patient/NN
cells/NNS
and/CC
MM-derived/JJ
cell/NN
lines/NNS
,/,
but/CC
pRB/NN
was/VBD
predominantly/RB
in/IN
its/PRP$
phosphorylated/JJ
form/NN
./.
=====
In/IN
MM/NN
cells/NNS
that/WDT
proliferated/VBD
in/IN
response/NN
to/TO
IL-6/NN
,/,
exogenous/JJ
IL-6/NN
downregulated/VBD
dephosphorylated/VBN
pRB/NN
and/CC
decreased/VBD
dephosphorylated/VBN
pRB-E2F/NN
complexes/NNS
./.
=====
Importantly/RB
,/,
culture/NN
of/IN
MM/NN
cells/NNS
with/IN
RB/NN
antisense/JJ
,/,
but/CC
not/RB
RB/NN
sense/NN
,/,
oligonucleotide/NN
(/(
ODN/NN
)/)
triggered/VBD
IL-6/NN
secretion/NN
and/CC
proliferation/NN
in/IN
MM/NN
cells/NNS
;/:
however/RB
,/,
proliferation/NN
was/VBD
only/RB
partially/RB
inhibited/VBN
by/IN
neutralizing/VBG
anti-IL-6/JJ
monoclonal/JJ
antibody/NN
(/(
MoAb/NN
)/)
./.
=====
In/IN
contrast/NN
to/TO
MM/NN
cells/NNS
,/,
normal/JJ
splenic/JJ
B/NN
cells/NNS
express/VBP
dephosphorylated/VBN
pRB/NN
./.
=====
Although/IN
CD40/NN
ligand/NN
(/(
CD40L/NN
)/)
triggers/VBZ
a/DT
shift/NN
from/IN
dephosphorylated/VBN
to/TO
phosphorylated/VBN
pRB/NN
and/CC
proliferation/NN
of/IN
B/NN
cells/NNS
,/,
the/DT
addition/NN
of/IN
exogenous/JJ
IL-6/NN
to/TO
CD40L-treated/JJ
B/NN
cells/NNS
does/VBZ
not/RB
alter/VB
either/CC
pRB/NN
or/CC
proliferation/NN
,/,
as/IN
observed/VBN
in/IN
MM/NN
cells/NNS
./.
=====
These/DT
results/NNS
suggest/VBP
that/IN
phosphorylated/VBN
pRB/NN
is/VBZ
constitutively/RB
expressed/VBN
in/IN
MM/JJ
cells/NNS
and/CC
that/IN
IL-6/NN
further/RB
shifts/VBZ
pRB/NN
from/IN
its/PRP$
dephosphorylated/JJ
to/TO
its/PRP$
phosphorylated/JJ
form/NN
,/,
thereby/RB
promoting/VBG
MM/NN
cell/NN
growth/NN
via/IN
two/CD
mechanisms/NNS
;/:
by/IN
decreasing/VBG
the/DT
amount/NN
of/IN
E2F/NN
bound/VBN
by/IN
dephosphorylated/VBN
pRB/NN
due/IN
to/TO
reduced/VBN
dephosphorylated/VBN
pRB/NN
,/,
thereby/RB
releasing/VBG
growth/NN
arrest/NN
;/:
and/CC
by/IN
upregulating/VBG
IL-6/NN
secretion/NN
by/IN
MM/NN
cells/NNS
and/CC
related/JJ
IL-6-mediated/JJ
autocrine/JJ
tumor/NN
cell/NN
growth/NN
./.